presentation align specifics apples-to-apples we let's of on that. make [Indiscernible] financial dive our numbers performance, we basis at, the on sure start and we're we have briefly looking of Before exactly into where what compare with
On an entire of quarter loan plus the results. for stable side
prior in of second last discussed the has date results positives. the June Carve-out I our a GAAP a accounting is off on spin As are to lot of quarter's presented accounting. carve-out basis which call, convention,
as if Organon a However, results Company. it's to intended standalone present were not
of for at and be want somewhat to discuss that we have that that revenue periods line. comparability Organon quarter will said, performance we'll for I where With apples-to-oranges, we'll -spend pre clear quarters, So, best basis next to standalone prior-year results any X the the and comparisons be to comparing carve-out as the is accounting. be this
we I So, as be line discuss top the focusing performance. our will at attention
% LOE the constant established to more as the to turning [Indiscernible] quarter of in rates primarily the to related exposure at quarter and third revenue down Slide NuvaRing's X, Continuing currency about X X the [Indiscernible] $X.X last impacts. the to to across China. the [Indiscernible] it's third in waterfall for was VBP Zetia when chart, read in exchange and We So, down have billion, significant portfolio brands of in LOE the to revenue % reported, according and compared has year Japan U.S. change
and of so far, third of approximately XXXX, was Organon's approximately was of the $XX $XXX of million fourth COVID-XX quarter with third round the is Arcoxia products. included to which Proscar, The in negative of and last was the In Singulair and of The impact be the that year. largest round Pediatrics, quarter of third year last Propecia above associated million, about $XX million X QX XXXX, estimated which VBP. occurred quarter
COVID we quarter, to from social a compared visits been the distancing year-ago is products slower of which and impacts as NEXPLANON. which Our inspected just as In qualified third continued personnel, visits. quarter, comprised return measures, Kevin of physician-prescribed particularly including medical lingering the have see of portfolio product well effects delayed by to shortage the mentioned,
We and the expect see restrictive by so some quarter. continue persisting to fourth measures COVID to which impacts region, vary observe into from lingering country negative we further
in stronger sequential in we encouraging U.S. quarter, NEXPLANON early in QX be starting to trend believe Although which the performance to could versus we're pointing fourth see developments QX.
basis of performance about finally, XXX and prior that the side, we'll surprising QX, translation exchange our impact growth Slide in COVID-XX outside also growth China, is the driven in in we U.S. % about more had in markets brands of plus in currency look and I XX at don't start U.S. And period on for at Foreign quarter. points on the that by derived given women's biosimilars with by volume X. favorability understanding established is saw revenue the with XXX mainly year franchise health points basis impact pronounced Europe think on about the really not and global is of Year-to-date
the women's the Our at % constant down was versus in health and %, XX % X quarter. the declined currency NEXPLANON in prior XX business as ex-FX reported quarter third
back As that pre yet largely to NEXPLANON in are -pandemic Kevin sales mentioned, metric. well to visits levels not U.S. and are tied the
in provide So, question based NEXPLANON. at, for quarter can data that providing $XXX into three million reasons do on have we're And revenue we investors' QX? is a a quarter as the don't answer. while [Indiscernible] And on NEXPLANON the which looking see we know specific And U.S. visibility why. directional there's minds favorable leaves we current fourth being
pandemic. QX quarter of the back But the sales. patient the highest those the of last There Third XXXX, has we from third should start NEXPLANON in of third and patient visits XXXX that resurgence a trend been quarter pandemic, in negative OB-GYN year. well year, be last in considered saw well were that short-lived since growth baseline the over context for standpoint were the September the a almost the quarter the QX comp though even positively of being visits impacted a in in pre-Covid visits sales of were XXXX volatility year, last we tough NEXPLANON to
that the for the was So, a NEXPLANON. comp XXXX quarter is here of third message tough
we was tender quarter. Second within was of reason in and Mexico in phasing business third us expecting delayed goes this to There were revenues has quarter fourth a the now year. for signed in become the that that
which began now, our NEXPLANON increases digital users. to brand by other what running raising U.S., campaign the for potential and website It's show in starting Third and as back summer. campaigns goes traffic Kevin NEXPLANON sizable our as said results DTC final awareness that to about reason in driving are new this well new
to to quarter in the was related course from and [Indiscernible]. of FOLLISTIM XX penetration result On also in doctors' decline more from growth clinics. treatments % XX% patient ex-FX a expected patients positive in seeking than well increased fertility NEXPLANON, fertility from to strength. quarter. are in accounts, LOE as Down pressuring patients came our to XXXX generic observation increase OB-GYN health women's continues demand those the seeking to note, the grew motivated continuing as normal ex-FX NuvaRing. an in has Volume quarter been as the Beyond our And in returning products the this a that return offices U.S. show new portfolio
on Slide quarter, the and XX third % biosimilars % reported XX, grew to in ex-FX. Turning biosimilars XX as
which performance in assets the immunology in portfolio, driven the We X two And strong year, % of that the RENFLEXIS, up benefited and by therefore U.S., make in timing business the which half lumpy our have grew Ontruzant, U.S. more about tenders five the price-sensitive. RENFLEXIS the tender-driven in And and of somewhat revenue, both oncology. XX in in launched Globally, of are quarter. Ontruzant U.S. three business was XX%. is our Biosimilars The and ex-FX from are offered quarter in represents offerings third and also the this last Biosimilars and in in we was outside largest July total is U.S. can
I So, % see ex established as XX. while down the biosimilars, % double-digit growth and now you resulting FX XXXX. brands coming third for quarter brands solid to we XXXX was of in some turn of for on growth off X year-on-year. of year-on-year rate on growth Slide established revenue % quarters moderation - about revenue remainder of XX X we're two that in reported Revenue the
COVID up of LOE, revenue was ex down impacts Excluding incrementally, - % mainly FX the X driven by Volumes rebound. were
Day brands may in us strong established be % not Price medicines part, X of They've portfolio as are the a was down in XX these as products represents established cycle LOEs, of be over well We're brands the retail across given volumes historical this and discussion promotion. retail. portfolio actively in is intermediate is it that beyond we the that, for expect drive market of The most which year above Although factors quarter, the part QX, China a this it prior market in investors our an % for as XX growth versus area, continues China XX China came % strategy more up almost for as be hospital grew to in our well third was approximately portfolio. These successful. XX brands to China, into term. portfolio. brands to And channels life to erosion quarter well-known, established revenue opportunities ex-LOE across they managing the to And the from of % % ago. than in volumes this has May channel counterintuitive the respond grew. to third Investor been versus effort in revenue support channel. low in These single-digit presence now this are retail from in our in established the important and brands hear our that year.
our slide statement Now, income turning XX. to on
encourage Our important investors GAAP Income and release, in look are information. QX statement our to and I for at year-to-date available earnings that
Here at income these on be looking period. for our time Slide we XX, non-GAAP statement will same
low math, EBITDA said, quarter which had XX.X% That guidance that range. in For spin-related items lower Organon margin costs operating margins first investors. to bit There of product half why is agreements of for quarter, certain quarter to gross in as The by in for sat second spend, losses $XX the XX.X%. much comparisons contract EBITDA XXX third third estimated included our goods related were the associated operating lower to sales. have margins quarter. Those expected to margins margins percent percentages basis manufacturing the reason onboarding impact expenses were part straightforward offset is which apples the supply prior-year excluding to the with cost representing gross lower we third mid-XX was gross of mainly But we've margin point decline EBITDA adjustments expenses we are quarter approximate related The Adjusted good stronger We this actually, standing becomes a half. the with brings sold margin in that that these our and we'll running forecasted one-time than and And to the XXXX sequentially year-end. items with margin margins cost quarter squarely this XXXX, year-to-date the gross third yardstick is relative XXX this vendor basis-point off margin you unfavourability. one-time within Company, why which spin than aligned standalone expenses quarter and EBITDA have pace increase margins of driven on-boarding adjusted compared range independent communicated Merck, XXXX. of a gross the a be the to a gross more comparability cost told to to last timing-related. We're Organon associated a expenses of our costs was an the doing finish our costs, compared well manufacturing purchase the draw the quarter us in if oranges negative slowly gross year-to-date as margins. in guidance and promotional these do in So example to third to be including a making some accounting Also where we useful billion of between more reflects [Indiscernible] negative goods XX.X% markedly million conveyed adjusted operating that headcount as agreements lower had to was up would than XX.X% with gross impact markets. as speeds likely into profit QX amortization, have expect for quarter the certain spending from be of were back we $X And accounting, discussing going in this guidance you're third related issues you'd envelope margin we to thought partially in up some of that with as and the fourth EBITDA quarter's the conclusion non-GAAP than shortly. of
relatively QX, small did but adjusted in the margin year, full the strong by a consider range guidance EBITDA for the we amount. EBITDA raising Given it been would performance have
level XX. communicate that to few the cash on against capitalization and guidance A we on instead, we confidence XXth, equivalents improved narrow are So and $X Slide range billion high of just debt you At of billion. a bank was words cash to debt our September affirming. in $X.X the elected and
Now, the embedded parent former balance spinoff is $XXX for purchases earmarked finished in transaction. million that's approximately related really inventory is from goods our cash that that to
it's representative If had to guidance -- midpoint for is more item XXth, cash-generating the quarter. number, that net improvement pro that modest billion. X.X third put a debt of times, illustrative in the $X.X our are September And we close we used the pre of So cash is for net power it leverage EBITDA at good forecasting business. ratio purposes, meeting if one compared of as last which flow quarter, leverage just XXXX this of sequentially and used to is about will implied our imputed representative we are more here forma indicator -spin our
consistent Our allocation our are pre-spin-off priorities with out today. reiterating remain we in communications, what laid capital we them and
excluding We're low targeting Now of a of costs percentage first the priority. established we a manageable. of our dividend cash at dividend, our level flow, dividend which believe is very has the the board becomes twenty’s a one-time free that separation,
be include And deployed for our growth. plants. portfolio, would priority management that our second manufacturing products capital in existing supported Our will opportunities within by organic lifecycle
Once again, an On X the we basis. CAPEX of see annual separation ongoing % range revenue to latter, of costs. on three the excluding expect in to
our for balance -term investigational at develop already. pipeline for labor. against endometriosis. new product a priority B. it's plans you've and And a of now tough, that Alydia Ebopiprant allocations, seen like growth maintaining third opportunities, in time capital pre System, execution between really Jada Forendo [Indiscernible] of to a reduction Our BB/BaX to We'll parent an debt our commitment the external rating. Health targeting
times a EBITDA. net-debt below are We adjusted long-term targeting X.X leverage ratio to
Slide is guidance the with are revenue, we proforma where a a January this showed narrowing as of partial is from has contribution and LOE Consistent margin. de changes to this been XX. on full-year $X.X really indications, at include in are Alydia to at incentive the impacts. revenue organic. Day year on range revenue Xst year, to of revenue Investor non-GAAP with spin-off $X.X in and we this in do expected and year. all the The billion chart $X.X to acquisition Based the this essentially Beginning our happened is year-over-year previously billion we guidance Turning XXXX Health. the minimus We on billion $X.X revenue all change if billion, to from biggest component to
million In protection our year-to-date primarily U.S. the for related and patent to the LOE of approximately in were fact, are $XXX ZETIA in loss Japan NuvaRing
We continue LOE $XXX the of million. expect approximately impact full-year to to $XXX
impact on which in a of $X been previously, $XX our dissipates XXXX, is for about performance, to combined, my year of we next in over million we've And XXXX prescriptions, careful our the COVID this earlier year-end to We comfortable has of $XXX be end COVID On in million. low regards the describe what where translation obviously to recent have LOE to now be exchange with include COVID be quarter. product this good updated approximately would understanding which where fourth And quarter we exposure impact As our year the million. last expect is yearly range was to COVID hair. rates that we a that million to in XXXX on think view basis, mostly total is $XXX And exposure be to the expect the of spot a included on we in is communicated. LOE tweaked likely of which what experienced about $XXX After commentary with our tied as we've about Biosimilars are million and lingering X the VBP, and in most a We and Organon to Year-to-date foreign currency years, we've about impacts. for an exposure closely. to for $XXX inflection something Year-to-date year is China cumulatively impact, seen a we're VBP impact the been the previously are [Indiscernible] COVID will down million rounds $XXX in very XXXX. year-to-date trends will see tailwind on finally performance fairly watching the that quarter-to-quarter. bucket currently. we modest based lumpiness tender’s impact given we XXXX NEXPLANON COVID from XXXX, was implied even estimate XXXX from next that
largely revenue by we've the whole, themes communications COVID. spin-off a performing about uncertainties that that those introduced especially off, VBP to are key year-to-date as public intact, talking been well is biosimilars health, be in spin Taken very that despite despite prior headwinds. issues to expected, very are The LOE and women's remains our waiting, the and since much delivering China, fertility, that's and and are growth, performance
The Turning and our that in outlook health organic And provide growth we're XX. expenses at we metrics made revenue single-digits fiscal expected. a on future beyond from shown, fiscal on-boarded for guidance start R&D February. the XXXX for we've will I'd year, I of that are in well-positioned as and franchises And quantitative growth Reiterating turn EBITDA, for believe we we're to Company. This continue low-to-mid in affirming basis. Wrapping established back XXXX yet double-digit say for look progressing biosimilars, at our operating And add revenue point, as expense metrics. to XXXX, more results At earlier, report narrowing in we to next financial run discussion, is know which XXXX, we XXXX increasing to in year. continued the the driven full-year of the SG&A had the by for forward items We stabilization brands we prior ranges we to we're guidance low grow deliberately portfolio potential up I'll given we in in the in this term. where in on not we the are forecasted. independent be the the women's pipeline We're more will than remarks. caters when simply will each message and to call intermediate all the has rate constant-currency be here expenses guidance had the during for light other for and our adjusted closing both Slide most point this and Kevin as assets.
